ReviewFrontiers in immunology2022
CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.Journal of translational medicine · 2025Trial
- CAR T therapy in adult DLBCL patients in Slovenia: Evaluation of predictive scores for outcomes and adverse events.Human vaccines & immunotherapeutics · 2026Article
- Racial and clinical determinants of response in 2304 large B-cell lymphomas treated with CD19 CAR T in clinical trials.Blood advances · 2026Article
- Epigenetic editing to advance CAR T cell therapy.Clinical epigenetics · 2026Review
- The impact of the large B-cell lymphoma tumor microenvironment on efficacy of CD19-directed CAR-T immunotherapy.Frontiers in immunology · 2026Review
- Granzyme B PET Imaging Enables Detection of CAR T-Cell Therapy Response in a Human Melanoma Mouse Model.Diagnostics (Basel, Switzerland) · 2025Article
- Predictors of response to CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a consolidated review.Current opinion in oncology · 2025Review
- Case Report: Rare adverse events following CAR-T therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.Frontiers in oncology · 2025Article
- Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024.Frontiers in immunology · 2025Review
- Survival prediction in diffuse large B-cell lymphoma patients: multimodal PET/CT deep features radiomic model utilizing automated machine learning.Journal of cancer research and clinical oncology · 2024Article
- Co-stimulation of CD28/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness.Molecular therapy. Oncology · 2024Article
- Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.Cancer medicine · 2024Article
- Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.Journal for immunotherapy of cancer · 2024Article
- Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies.International journal of molecular sciences · 2024Review
- Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives.Frontiers in immunology · 2024Review
- CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?Seminars in hematology · 2023Review
- Potency assays and biomarkers for cell-based advanced therapy medicinal products.Frontiers in immunology · 2023Review
- Autologous stem cell transplantation meets CAR-T therapy: A synergistic strategy for B-cell lymphoma.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy with T cells genetically modified with chimeric antigen receptors (CARs) has shown significant clinical efficacy in patients with relapsed/refractory B-cell lymphoma. Nevertheless, more than 50% of treated patients do not benefit from such therapy due to either absence of response or further relapse. Elucidation of clinical and biological features that would predict clinical response to CART19 therapy is of paramount importance and eventually may allow for selection of those patients with greater chances of response. In the last 5 years, significant clinical experience has been obtained in the treatment of diffuse large B-cell lymphoma (DLBCL) patients with CAR19 T cells, and major advances have been made on the understanding of CART19 efficacy mechanisms. In this review, we discuss clinical and tumor features associated with response to CART19 in DLBCL patients as well as the impact of biological features of the infusion CART19 product on the clinical response. Prognosis of DLBCL patients that fail CART19 is poor and therapeutic approaches with new drugs are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.